RENAL DENERVATION DEVICES MARKET ANALYSIS

The global renal denervation devices market size was valued at US$ 903.9 million in 2023 and is expected to reach US$ 2,332.1 million by 2030, at a CAGR of 14.5% from 2023 to 2030. Renal denervation is a minimally invasive, investigational procedure to treat hypertension (high blood pressure) that has not improved with other treatments. This type of hypertension is called resistant hypertension.

Renal Denervation Devices Market Regional Insights

• North America accounted for the largest market share of over 55% in 2023 and is projected to remain dominant over the forecast period. The high prevalence of hypertension and the presence of key market players are the key factors driving the growth of the market in this region.
• Europe is the second-largest market for renal denervation devices. The increasing product launches by the market players. Additionally, growing awareness about the renal degenerative disorder and the availability of advanced healthcare facilities are also contributing to the market growth.
• Asia Pacific is the fastest-growing market for renal denervation devices owing to the increasing geriatric population and the rising number of chronic diseases among the population. These factors will aid in the market growth over the forecast period.

Figure 1. Global Renal Denervation Devices Market Share (%), by Region, 2023

To learn more about this report, request sample copy

Analyst’s Views on the Global Renal Denervation Devices Market:

The global renal denervation devices market is expected to grow at a rapid rate owing to the increasing prevalence of hypertension among the population and increasing inorganic strategies among industry players will aid in the market growth over the forecast period

Renal Denervation Devices Market Drivers

• The rising prevalence of hypertension globally is expected to drive the market growth over the forecast period. For instance, according to the data published by the Center for Disease Control and Prevention (CDC) on July 6, 2023, globally nearly half of adults have hypertension (48.1%, 119.9 million), defined as a systolic blood pressure greater than 130 mmHg or a diastolic blood pressure greater than 80 mmHg or are taking medication for hypertension.
• Increasing obese population globally will aid in the market growth over the forecast period. For instance, according to the data published by the World Health Organization (WHO) on June 9, 2021, more than 1.9 billion adults, and 18 years and older, were overweight.

Renal Denervation Devices Market Opportunities

• The emerging markets in Asia Pacific and Latin America regions present a great opportunity for growth in the global renal denervation devices market over the coming years. These regions are experiencing rapid economic development and growth in incomes. Along with growth, countries are witnessing significant changes in lifestyles and diets which is leading to rise in non-communicable diseases like hypertension.

 Renal Denervation Devices Market Trends

• The increasing focus on radiofrequency-based renal denervation technologies is having a significant impact on the global renal denervation devices market. Traditionally, renal denervation treatments have relied on ultrasound-based techniques to disrupt renal nerves through either ablation or damage. However, recent clinical studies have demonstrated the advantages of radiofrequency (RF) energy delivery systems over other modalities in achieving effective and long-lasting renal denervation.

Renal Denervation Devices Market Restraints

• The high procedural costs associated with renal denervation devices and the procedure is a major factor restraining the growth of the global renal denervation devices market. Renal denervation is a minimally invasive procedure that uses a catheter-based ablation technique to deactivate the renal nerves and lower blood pressure in patients with uncontrolled high blood pressure. However, the entire cost of the renal denervation procedure is placed on the patient unlike pharmaceutical therapy where some costs may be covered by insurance.

Recent Developments

New Product Launches

• In November 17, 2023, Medtronic, a medical device company, received approval from the U.S. Food and Drug Administration (FDA) Medtronic Symplicity Spyral renal denervation system for use in the U.S.
• In November 10, 2023, Recor Medical, Inc., a medical device company, announced the first commercial use of Recor’s Paradise Ultrasound Renal Denervation (uRDN) system for the treatment of hypertension, the first U.S.FDA approved renal denervation therapy in the U.S.

Figure 2. Global Renal Denervation Devices Market Share (%), by Procedure Type, 2023

To learn more about this report, request sample copy

Top Companies in the Renal Denervation Devices Market

• Medtronic
• Recor Medical, Inc.
• Boston Scientific Corp
• Kona Medical
• Terumo Corporation
• Abbott
• Ablative Solutions
• Others

Definition: Renal denervation devices are medical devices used in the treatment of resistant hypertension, a condition where a patient's high blood pressure is unresponsive to traditional therapies such as medications. Resistant hypertension is a serious health condition that increases the risk of heart attack, stroke, kidney disease, and other complications.

Few Other Promising Reports in the Medical Device Industry

Renal Biomarkers Market

Urology Device Market